Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.8K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.8K
Inhaled Medications01:23

Inhaled Medications

912
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
912
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.0K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

960
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
960
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension.

Nature communications·2018
Same author

Ca<sup>2+</sup> handling remodeling and STIM1L/Orai1/TRPC1/TRPC4 upregulation in monocrotaline-induced right ventricular hypertrophy.

Journal of molecular and cellular cardiology·2018
Same author

Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension.

The Journal of clinical investigation·2018
Same author

Rapid Contour-based Segmentation for <sup>18</sup>F-FDG PET Imaging of Lung Tumors by Using ITK-SNAP: Comparison to Expert-based Segmentation.

Radiology·2018
Same author

Risk assessment in pulmonary arterial hypertension.

The European respiratory journal·2018
Same author

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies.

Pulmonary circulation·2018

Related Experiment Video

Updated: Mar 2, 2026

Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

12.4K

Ciclesonide: a novel inhaled corticosteroid.

Marc Humbert1

  • 1Hôpital Antoine Béclère, Service de Pneumologie et Réanimation Respiratoire, Assistance Publique Hôpitaux de Paris, Université Paris-Sud, 157 Rue de la Porte de Trivaux, 92140 Clamart. marc.humbert@abc.ap-hop-paris.fr

Expert Opinion on Investigational Drugs
|October 6, 2004
PubMed
Summary
This summary is machine-generated.

Ciclesonide, a novel inhaled corticosteroid (ICS), offers effective asthma treatment with fewer side effects than traditional ICS. Its unique activation in the lungs enhances safety and efficacy for persistent asthma management.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.6K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K

Related Experiment Videos

Last Updated: Mar 2, 2026

Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

12.4K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.6K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K

Area of Science:

  • Pulmonology and Pharmacology
  • Respiratory Medicine
  • Drug Development

Background:

  • Persistent asthma affects millions globally, necessitating effective treatments.
  • Current inhaled corticosteroids (ICS) manage asthma but carry risks of local (hoarseness, oral candidiasis) and systemic adverse effects (adrenal suppression, osteoporosis, cataracts).
  • There is a need for ICS with comparable efficacy and an improved safety profile.

Purpose of the Study:

  • To evaluate ciclesonide, a novel ICS, for its efficacy and safety in treating persistent asthma.
  • To assess ciclesonide's potential to reduce local and systemic adverse events associated with conventional ICS.

Main Methods:

  • Ciclesonide is a prodrug, inactive until reaching the lungs.
  • It is converted to its active metabolite, desisobutyryl-ciclesonide, in the target tissue.
  • Pharmacokinetic and pharmacodynamic properties including high protein binding, low oral bioavailability, and rapid clearance were evaluated.

Main Results:

  • Ciclesonide demonstrates comparable airway anti-inflammatory efficacy to existing ICS.
  • Its targeted activation and pharmacokinetic profile contribute to a reduced risk of local adverse events.
  • Favorable systemic safety profile observed due to low oral bioavailability and rapid clearance.

Conclusions:

  • Ciclesonide represents a promising novel inhaled corticosteroid for persistent asthma.
  • It offers effective asthma control with a potentially improved safety profile, minimizing local and systemic side effects.
  • The drug's prodrug strategy and pharmacokinetic characteristics enhance its therapeutic index.